CAPR Stock Analysis: Buy, Sell, or Hold?
CAPR - Capricor Therapeutics Inc
$6.29
-0.54 (-7.97%)
âŧ
5d:
-5.41%
30d:
-66.74%
90d:
-78.32%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 12, 2026 at $4.28 · last confirmed Aug 21, 2026
Strength: 10.0/10
Get Alerted When CAPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CAPR is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CAPR is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CAPR is currently trading at $6.29, which is considered slightly low relative to its 30-day fair value range of $3.29 to $17.30. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.1) compared to its historical average (133.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAPR is in a strong downtrend. Immediate support is located at $3.73, while resistance sits at $8.29. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.50 (+66.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CAPR is in a strong downtrend. Immediate support is located at $3.73, while resistance sits at $8.29. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $10.50 (+66.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.29 -
$17.30
Company Quality Score
41/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
74.8%
Protect Your Profits
Holding CAPR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 66.9% below Wall St target ($10.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.29 -
$17.30
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.73
Resistance Level
$8.29
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.12
Wall Street Target
$10.50
(+66.9%)
Revenue Growth (YoY)
-7.9%
PE vs Historical
-4.1 vs 133.6
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 9:21 AM ET
Data refreshes hourly during market hours. Next update: 10:21 AM
Data refreshes hourly during market hours. Next update: 10:21 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Karimah Es Sabar
SELL
7529 shares
2026-04-02
Karimah Es Sabar
SELL
53735 shares
2026-04-01
Anthony Bergmann
SELL
25000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 38 SELL |
Advanced CAPR Option Strategies
Professional options setups generated by AI based on today's CAPR price and gamma walls.
